Please join us for our symposium on November 3 from 5:10 p.m. – 6:40 p.m. PT, titled, “A Promising Biomarker for Tumor Immunogenicity: Unveiling the Potential of Immunoscore® IC (CD8/PDL1) Assay.”

This symposium will showcase the Immunoscore® IC (Immune Checkpoints CD8/PDL1) assay. Experts will provide an in-depth review of the assay’s analytical performance, clinical relevance, and efficacy, with a focus on metastatic colorectal cancer (mCRC) and non-small cell lung cancer (NSCLC).

Join us to engage in a dynamic discussion with our experts, addressing key questions, potential challenges, and future directions in harnessing Immunoscore® IC for precision immunotherapy.

If you are unable to attend our symposium, be sure to stop by Booth #319 to meet with our team.